Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions

Appoints Paul Michaels Co-CEO of Parent and CEO of Subsidiary

Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, today announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset licensing within the country. The establishment of this subsidiary marks an important milestone for Curative Biotech as it expands its reach and presence in the Japanese market. The new entity has been named Curative Biotech Japan K.K. (“Curative Japan”) and will be located at 2-23-12 Shimomeguro Meguro ku, Tokyo 153-0064 Japan.

Read more at globenewswire.com

Related news for (CUBT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.